| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Ethyl linolenate does not have a specific pharmacological target. It is a fatty acid ethyl ester used as a reference molecule and research reagent.
|
|---|---|
| ln Vitro |
Tyrosinase activity is inhibited and Forskolin-induced melanogenesis is markedly blocked by ethyl linolenate[1].
Ethyl linolenate is being studied as a possible skin whitening agent with anti-melanogenesis activity. As a fatty acid ethyl ester, it can be incorporated into lipid bilayers and lipid-based delivery systems. Its role as a reference molecule in alcohol research stems from the fact that fatty acid ethyl esters are formed in the body through the non-oxidative metabolism of ethanol. |
| ln Vivo |
In vivo, fatty acid ethyl esters like ethyl linolenate are formed in the body through the non-oxidative metabolism of ethanol. Their measurement in biological samples can serve as a biomarker of alcohol consumption. Ethyl linolenate may be used as a reference molecule in systems developed to measure fatty acid esters derived from tissues, membranes, and lipids.
|
| Enzyme Assay |
In vitro assays are conducted to study the properties of ethyl linolenate as a fatty acid ethyl ester. It is used as a reference standard in analytical chemistry methods such as gas chromatography-mass spectrometry (GC-MS) for the quantification of fatty acid esters in biological samples. Its anti-melanogenesis activity is studied in cell-based assays using melanocytes.
|
| Cell Assay |
In vitro cell-based assays are conducted to evaluate the anti-melanogenesis activity of ethyl linolenate using melanocyte cell lines. The compound's effects on melanin production and tyrosinase activity are assessed.
|
| Animal Protocol |
In vivo studies involving ethyl linolenate are primarily focused on its role as a biomarker of alcohol consumption. Fatty acid ethyl esters like ethyl linolenate are measured in biological samples (e.g., blood, urine) to assess ethanol exposure.
|
| ADME/Pharmacokinetics |
Ethyl linolenate is a lipophilic compound that can be incorporated into lipid bilayers and lipid-based delivery systems. As a fatty acid ethyl ester, it is formed in the body through the non-oxidative metabolism of ethanol. Its measurement in biological samples serves as a biomarker of alcohol consumption.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for ethyl linolenate. As a fatty acid ethyl ester, it is generally considered to be of low toxicity. However, it may pose rancidity problems in cosmetic formulations.
|
| References | |
| Additional Infomation |
Ethyl linoleate is a transparent, colorless liquid. (NTP, 1992)
Ethyl linoleate is a long-chain fatty acid ethyl ester formed by the condensation of the carboxyl group of linolenic acid and the hydroxyl group of ethanol. It is a metabolite in both humans and plants. Its function is related to α-linolenic acid. Ethyl linoleate has been reported to exist in Daphne odora, Lantana ukambensis, and other organisms with relevant data. Ethyl linolenate is a long-chain fatty acid ethyl ester derived from linolenic acid. It is used as a reference molecule in alcohol research and is being studied as a possible skin whitening agent. It is not a drug and is not approved for human therapeutic use. |
| Molecular Formula |
C20H34O2
|
|---|---|
| Molecular Weight |
306.48
|
| Exact Mass |
306.255
|
| CAS # |
1191-41-9
|
| Related CAS # |
Ethyl linolenate-d5;203633-16-3
|
| PubChem CID |
5367460
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
374.4±0.0 °C at 760 mmHg
|
| Flash Point |
100.7±20.4 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.475
|
| LogP |
7.49
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
22
|
| Complexity |
327
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C([H])([H])[H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(\[H])/C([H])([H])/C(/[H])=C(\[H])/C([H])([H])/C(/[H])=C(\[H])/C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
JYYFMIOPGOFNPK-AGRJPVHOSA-N
|
| InChi Code |
InChI=1S/C20H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-4-2/h5-6,8-9,11-12H,3-4,7,10,13-19H2,1-2H3/b6-5-,9-8-,12-11-
|
| Chemical Name |
ethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (326.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.16 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2629 mL | 16.3143 mL | 32.6286 mL | |
| 5 mM | 0.6526 mL | 3.2629 mL | 6.5257 mL | |
| 10 mM | 0.3263 mL | 1.6314 mL | 3.2629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
